PCSK9 and diabetes mellitus: The combination therapy of ezetimibe, a PCSK9 inhibitor, and bempedoic acid reduced the patient's 10-year cardiovascular disease risk from 5.2% to 3.5%, as calculated using the SCORE2-Diabetes system.